PTEN Deficiency as a Predictive Biomarker of Resistance to HER2-Targeted Therapy in Advanced Gastric Cancer

Publisher： Karger

E-ISSN： 1423-0232|88|2|76-85

ISSN： 0030-2414

Source： Oncology, Vol.88, Iss.2, 2014-10, pp. : 76-85

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeted HER2 Treatment in Advanced Gastric Cancer

By  

Oncology, Vol. 78, Iss. 1, 2010-02 ,pp. : 26-33

Karger

Access to resources Recommend Favorite

Targeted Therapy in HER2-Positive Breast Cancer

By  

Oncology Research and Treatment, Vol. 39, Iss. 5, 2016-04 ,pp. : 295-302

Karger

Access to resources Recommend Favorite

Targeted Therapy of HER2-Negative Breast Cancer

By  

Oncology Research and Treatment, Vol. 39, Iss. 3, 2016-02 ,pp. : 118-121

Karger

Access to resources Recommend Favorite

Targeted therapy in gastric cancer

By  

APMIS (ELECTRONIC), Vol. 123, Iss. 5, 2015-05 ,pp. : 365-372

John Wiley & Sons Inc

Access to resources Recommend Favorite

Resistance to HER2-targeted therapy: mechanisms of trastuzumab resistance and possible strategies to overcome unresponsiveness to treatment

By Hubalek Michael  

Wiener Medizinische Wochenschrift, Vol. 160, Iss. 19-20, 2010-11 ,pp. : 506-512

Springer Publishing Company

Access to resources Recommend Favorite